- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Clinical Review Report: Tenofovir Alafenamide (Vemlidy): (Gilead Sciences Canada, Inc.): Indication: Treatment of chronic hepatitis B in adults with compensated liver disease [Internet].
Source
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr.
CADTH Common Drug Reviews.
Excerpt
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tenofovir alafenamide for the treatment of adults with chronic hepatitis B (CHB) and compensated liver disease.
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.
Sections
Abbreviations
Executive Summary
Introduction
Objective and Methods
Results
Discussion
Conclusions
Appendix 1. Patient Input Summary
Appendix 2. Literature Search Strategy
Appendix 3. Excluded Studies
Appendix 4. Detailed Outcome Data
Appendix 5. Validity of Outcome Measures
Appendix 6. Summary of Open-Label Studies
Appendix 7. Summary of Natural History, Diagnosis, Management, and Prognosis of HBV
References
PMID:
30475544
Free Books & DocumentsFree full text
|
|